Heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-25. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
1993/2828) Finance Act 1993, section 211, (Appointed Day) Order 1993 (S.I. 1993/2831) A61 Trunk Road (Sheffield to Westwood Roundabout) (Detrunking) Order 1993 (S.I. 1993/2832) Building Societies (Aggregation) Rules 1993 (S.I. 1993/2833) Mid Glamorgan Ambulance National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2834) Derwen National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2835) North Wales Ambulance National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2836) Rhondda Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2837) Velindre National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2838) Gwynedd Community Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2839) Nevill Hall and District National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2840) Gwynedd Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2841) Finance Act 1993, Chapter II, (Appointed Day) Order 1993 (S.I. 1993/2842) Payments to Redundant Churches Fund Order 1993 (S.I. 1993/2846) Ordination of Women (Financial Provisions) (Appeals) Rules 1993 (S.I. 1993/2847) East Anglian Ambulance National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2848) Norfolk Ambulance National Health Service Trust Dissolution Order 1993 (S.I. 1993/2849) Combined Probation Areas (Cumbria) Order 1993 (S.I. 1993/2852) Combined Probation Areas (Greater Manchester) Order 1993 (S.I. 1993/2853) Employment Appeal Tribunal Rules 1993 (S.I.
== Research == In 2018, the World Health Organization listed snakebite envenoming as a neglected tropical disease. In 2019, they launched a strategy to prevent and control snakebite envenoming, which involved a program targeting affected communities and their health systems. A policy analysis however found that the placement of snakebite in the global health agenda of WHO is fragile due to reluctance to accept the disease in the neglected tropical disease community and the perceived colonial nature of the network driving the agenda. Key institutions conducting snakebite research on snakebite are the George Institute for Global Health, the Liverpool School of Tropical Medicine, and the Indian Institute of Science.
== Sources == Tityus serrulatus, also known as the Brazilian yellow scorpion, is from the genus Tityus belonging to the family Buthidae. TsPep2 is identified from the venom of Tityus serrulatus by using a cDNA primer sequence based on the C-terminal amino acid sequence of KTx2 from Androctonus australis.
Sources: en.wikipedia.org
== Structure == SrtB overall structure is conserved in different gram-positive bacteria. The overall structure of SrtB in S. aureus as shown in the figure, consists of a unique eight-stranded β-barrel core structure and a two-helix subdomain at the N-terminal end. SrtB is similar in structure to SrtA with rmsd of 1.25Å but SrtB has more peripheral helices It has an N-terminal helical bundle and an α-helix between β6 and β7. The N-terminal extension present in SrtB relative to SrtA is very significant. It is known to place the two termini on the same side of the protein. This is believed to result in a different orientation of the protein on the surface of the cell, potentially affecting substrate access.
Gas chromatography–vacuum ultraviolet spectroscopy (GC-VUV) is a universal detection technique for gas chromatography. VUV detection provides both qualitative and quantitative spectral information for most gas phase compounds. GC-VUV spectral data is three-dimensional (time, absorbance, wavelength) and specific to chemical structure. Nearly all compounds absorb in the vacuum ultraviolet region of the electromagnetic spectrum with the exception of carrier gases hydrogen, helium, and argon. The high energy, short wavelength VUV photons probe electronic transitions in almost all chemical bonds including ground state to excited state. The result is spectral "fingerprints" that are specific to individual compound structure and can be readily identified by the VUV library. Unique VUV spectra enable closely related compounds such as structural isomers to be clearly differentiated. VUV detectors complement mass spectrometry, which struggles with characterizing constitutional isomers and compounds with low mass quantitation ions. VUV spectra can also be used to deconvolve analyte co-elution, resulting in an accurate quantitative representation of individual analyte contribution to the original response. This characteristically lends itself to significantly reducing GC runtimes through flow rate-enhanced chromatographic compression. VUV spectroscopy follows the simple linear relationship between absorbance and concentration described by the Beer–Lambert Law, resulting in more accurate retention time-based identification.
Mummies from Oceania are not limited only to Australia. Discoveries of mummified remains have also been located in New Guinea, New Zealand, and the Torres Strait, though these mummies have been historically harder to examine and classify. Prior to the 20th century, most literature on mummification in the region was either silent or anecdotal. However, the boom of interest generated by the scientific study of Egyptian mummification lead to more concentrated study of mummies in other cultures, including those of Oceania.
Sources: en.wikipedia.org
=== Side effects === Side effects in animals include transient hypertension and hypotension. Xylazine decreases both respiration rate and minute ventilation, although the changes to PaCO2 and PaO2 are minor and innocuous. Xylazine has been demonstrated to reduce the dose of epinephrine that causes arrythmia in dogs anaesthetised with isoflurane and halothane. Xylazine administration in sheep activates pulmonary macrophages that damage the capillary endothelium and alveolar type I cells. This in turns causes alveolar haemorrhage and oedema causing hypoxaemia. Intracarotid administration can cause seizures and excitement in horses. Xylazine has been shown to cause myometrial contractions in pregnant cattle. Further evidence of xylazine's effect on pregnant animals is lacking and although other a2 adrenergic receptor agonists have been shown to not cause the same myometrial contraction the administration of a2 adrenergic receptor agonists is not recommended and for animals near-term should only be used in specific circumstances. Xylazine affects the glucose level via the activation of alpha2A andrenergic receptors on beta cells, which prevents insulin release. alpha2 adrenergic receptors have been reported to cause transient hyperglycaemia with xylazine being reported as a cause in cattle and equine. The renal threshold for glucose is not exceeded due to the hyperglycaemia with clinical doses. An alpha2 adrenergic receptor antagonist can reverse the effect.
For services to Music. International list John Adams. Chair, British Retirement Home Association, Portugal. For services to the Community and Voluntary Organisations in Portugal. Joy Atkinson. Desk Officer, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Nicola Jane Barrett. Head, Corporate Services, British Embassy Moscow, Russia. For services to British Foreign Policy. Liza Barry. Deputy Director, Foreign, Commonwealth and Development Office. For services to National Security. Geoffrey James Booker. Founding Chairman and Field Director, The Quicken Trust and The GB Trust. For services to the community in Kabubbu, Uganda. Geraldine Elizabeth Booker. Director of Development, The Quicken Trust and The GB Trust. For services to the community in Kabubbu, Uganda. Sian Bowsley. Head, Agrifood and Sanitary and Phytosanitary (SPS), Windsor Framework Taskforce, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Christopher Mark Broadbent. Team Leader, Foreign, Commonwealth and Development Office. For services to National Security. Keith John Buckley. Chairman, British Chamber of Commerce, Macao; Chairman, The Lighthouse Club (Macao Branch) charity. For services to the Local Community and British Interests in Macao. Scott Arthur Burgess. Acting Overseas Security Manager, British Embassy Tehran, Iran. For services to the British Embassy Tehran. Adina Diana Esther Munroe-Charlow. Chairperson, Royal British Legion, Bahamas Branch. For services to Veterans in The Bahamas. Gillian Clasby.
==== Quantitative real-time polymerase chain reaction (qRT-PCR) ==== A more sensitive approach to transcript analysis of a gene is quantitative real-time polymerase chain reaction (qRT-PCR), which has also seen action in quantifying protease mRNA levels. Again, total RNA is extracted and used to generate cDNA for PCR amplification. As long as there is a specific primer for a protease, protease inhibitor, or interacting molecule, qRT-PCR can serve as a highly sensitive method to detect minuscule amounts of mRNA copy numbers per cell. A drawback that separates it from microarray analysis is its limited scope: a microarray can handle parallel analysis of multiple genes while qRT-PCR must amplify one mRNA for analysis at a time. It also suffers from the same limitation of microarray analysis regarding the lack of correlation between transcript and protein levels. However, its sensitivity lends it as a useful tool in validating microarray findings and quantifying specific protease transcripts of interest.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.